Patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) have better overall survival and progression free survival with continuous lenalidomide and low-dose dexamethasone compared to fixed duration front line regimens, real-world data shows. The retrospective trial compared the outcomes of NDMM patients within the UK Thames Valley Cancer Network who received one cycle of fixed duration ...
Sustained disease control with continuous lenalidomide in MM
By Nicola Garrett
4 Dec 2019